Pay in 4 interest-free payments of $7.30 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Additionally, 67% of participants treated with GSBR-1290 achieved at least a 6% reduction in weight within the 12-week study period
Pedre B, Barayeu U, Ezeria D, Dick TP
They also offer a generous reship policy and they are committed to the safe distribution of research peptides only to qualified researchers
The 2023 phase 2 double-blind, randomized controlled trial evaluating a GLP-1/GIP/glucagon receptor triagonist (retatrutide) in patients with the disease of obesity reported 24.2% weight loss at 48 weeks with 12 mg retatrutide
Rizvi SM, Shakil S, Biswas D, et al
US$ 21.02
US$ 26.30
US$ 25.83
US$ 28.30
US$ 23.73
US$ 20.58
